ILMN250502C80000
- 0.13
- -0.17-56.67%
Illumina Newsroom
Earnings Preview: Illumina to Report Financial Results Post-market on May 08
Getting In Cheap On Illumina, Inc. (NASDAQ:ILMN) Is Unlikely
Illumina And Ovation.io Launching GLP-1 Dataset To Accelerate New Therapy Development
Express News | Illumina and Ovation.io Launching First-of-Kind GLP-1 Dataset to Accelerate New Therapy Development
Illumina and Ovation.io Launching First-of-kind GLP-1 Dataset to Accelerate New Therapy Development
Even After Rising 3.7% This Past Week, Illumina (NASDAQ:ILMN) Shareholders Are Still Down 74% Over the Past Five Years
CCORF Maintains Illumina(ILMN.US) With Hold Rating, Cuts Target Price to $92
Illumina Is Maintained at Hold by Canaccord Genuity
Illumina Analyst Ratings
Should You Hold Illumina (ILMN)?
This Cancer Test Could Become Routine -- and a Big Seller, Says Analyst -- Barrons.com
Leerink Partners Maintains Illumina(ILMN.US) With Buy Rating, Announces Target Price $115
Bernstein Maintains Illumina(ILMN.US) With Hold Rating, Cuts Target Price to $90
Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations
Express News | Illumina Inc : Bernstein Cuts Target Price to $90 From $130
Illumina and Tempus Partner to Drive the Future of Precision Medicine Through Genomic AI Innovation
Bank of America lowers the Target Price for Illumina to $75.
Bank of America: Downgraded Illumina's Target Price from $90 to $75, maintaining a "underperforming Large Cap" rating. (Gelonghui)
Piper Sandler Maintains Illumina(ILMN.US) With Buy Rating, Maintains Target Price $190
Life Sciences Companies Likely to See Surprisingly Good 1Q Results -- Market Talk
BofA Securities Cuts Price Target on Illumina to $75 From $90, Keeps Underperform Rating